- €8.74bn
- €8.65bn
- €3.31bn
- 93
- 32
- 68
- 74
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,693 | 2,686 | 2,749 | 3,156 | 3,306 |
Cost of Revenue | |||||
Gross Profit | 2,205 | 2,196 | 2,310 | 2,629 | 2,735 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2,728 | 2,158 | 1,921 | 2,424 | 2,498 |
Operating Profit | -35.3 | 529 | 828 | 733 | 808 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -38.6 | 529 | 789 | 706 | 762 |
Provision for Income Taxes | |||||
Net Income After Taxes | -58.2 | 547 | 631 | 594 | 625 |
Minority Interest | |||||
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -50.8 | 548 | 647 | 649 | 644 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -50.7 | 548 | 647 | 649 | 644 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 4.8 | 8.02 | 7.82 | 8.55 | 5.26 |
Dividends per Share |